Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything
The drugmaker has a lot riding on continued clinical progress.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
Stocks have so far survived rising Treasury yields. But that may be about to change.
Strong earnings growth has cushioned the stock market from rising yields. But ever-rising bond rates may eventually take a toll.
Stocks have so far survived rising Treasury yields. But that may be about to change.
Strong earnings growth has cushioned the stock market from rising yields. But ever-rising bond rates may eventually take a toll.
Is Palantir Stock a Buy at 94 Times Sales?
Palantir's growth story is changing fast. See why commercial AI could reshape the company's earnings power, and why its premium valuation makes the next phase so important.
Five Below CMOO Sells 818 Shares at $248.88
Insider disposition represented 18% of directly held equity, leaving executive with 3,728 shares valued at roughly $900,000 post-transaction.
Iran War Has Cost U.S. Nearly $40 Billion and Fueled Inflation, CBO Finds
The report from the nonpartisan Congressional Budget Office estimates the war will cost the country another $2 billion to $3 billion each month it continues.
Solana lender Kamino taps Yieldstreet co-founder as CEO in Wall Street expansion
Michael Weisz will lead Kamino from a new New York headquarters as the DeFi lender is expanding into tokenized assets.